Supplemental material
Leukemia & Lymphoma
Volume 61, 2020 - Issue 2
Open access
3,252
Views
13
CrossRef citations to date
0
Altmetric
Original Articles
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
Heinz LudwigWilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria; Correspondence[email protected]
View further author information
, View further author information
Wolfram PönischDepartment of Hematology, University of Leipzig, Leipzig, Germany; View further author information
, Stefan KnopDivision of Hematology and Medical Oncology, Department of Internal Medicine II, Wuerzburg University Medical Center, Wuerzburg, Germany; View further author information
, Alexander EgleDepartment of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute – Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Austria; View further author information
, Axel HinkeCCRC Cancer Clinical Research Consulting, Düsseldorf, Germany; View further author information
, Martin SchrederDepartment of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria; View further author information
, Daniel LechnerDepartment of Medicine I, Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria; View further author information
, Roman HajekFakultní Nemocnice Ostrava, Ostrava, Czech Republic; View further author information
, Eberhard GunsiliusDepartment of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria; View further author information
, Andreas PetzerDepartment of Internal Medicine I, Ordensklinikum Linz – Barmherzige Schwestern, Linz, Austria; View further author information
, Katja WeiselUniversity Medical Center of Hamburg-Eppendorf, Hamburg, Germany; View further author information
, Dietger NiederwieserDepartment of Hematology, University of Leipzig, Leipzig, Germany; View further author information
, Hermann EinseleDivision of Hematology and Medical Oncology, Department of Internal Medicine II, Wuerzburg University Medical Center, Wuerzburg, Germany; View further author information
, Wolfgang WillenbacherDepartment of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria; ;Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria; View further author information
, Holger RumpoldDepartment of Oncology, Hematology and Gastroenterology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; View further author information
, Ludek PourDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic; View further author information
, Tomas JelinekFakultní Nemocnice Ostrava, Ostrava, Czech Republic; View further author information
, Karl Jochen KrenoszDepartment of Internal Medicine 3, Kepler Universitaetsklinikum GmbH, Med. Campus III, Linz, Austria; View further author information
, Angela MecklWilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria; View further author information
, Sandra NolteMedical Department, Division of Psychosomatic Medicine, Charité- Universitätsmedizin, Berlin, GermanyView further author information
, Thomas MelchardtDepartment of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute – Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Austria; View further author information
, Richard GreilDepartment of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute – Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Austria; View further author information
& Niklas ZojerDepartment of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria; View further author information
show all
Pages 377-386
|
Received 24 Jun 2019, Accepted 07 Sep 2019, Published online: 26 Sep 2019
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.